Senolytic Agent Navitoclax Inhibits Angiotensin II-Induced Heart Failure in Mice.
Jia K, Dai Y, Liu A, Li X, Wu L, Lu L, Bao Y, Jin Q.
J Cardiovasc Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1097/fjc.0000000000000878 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för navitoclax. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
27 hitsClearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-X<sub>L</sub> -BAX interaction.
Saleh T, Carpenter VJ, Tyutyunyk-Massey L, Murray G, Leverson JD, Souers AJ, Alotaibi MR, Faber AC, Reed J, Harada H, Gewirtz DA.
Mol Oncol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/1878-0261.12761Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small-cell lung cancer cells.
Ohgino K, Terai H, Yasuda H, Nukaga S, Hamamoto J, Tani T, Kuroda A, Arai D, Ishioka K, Masuzawa K, Ikemura S, Kawada I, Naoki K, Fukunaga K, Soejima K.
Cancer Sci · research-article; journal article · DOI 10.1111/cas.14569Navitoclax (ABT263) reduces inflammation and promotes chondrogenic phenotype by clearing senescent osteoarthritic chondrocytes in osteoarthritis.
Yang H, Chen C, Chen H, Duan X, Li J, Zhou Y, Zeng W, Yang L.
Aging (Albany NY) · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/aging.103177Inhibition of EGFR pathway promotes the cytotoxicity of ABT-263 in human leukemia K562 cells by blocking MCL1 upregulation.
Lee YC, Wang LJ, Huang CH, Chiou JT, Shi YJ, Chang LS.
Biochem Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bcp.2020.114047The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice.
Sharma AK, Roberts RL, Benson RD, Pierce JL, Yu K, Hamrick MW, McGee-Lawrence ME.
Front Cell Dev Biol · research-article; journal article · DOI 10.3389/fcell.2020.00354Endoplasmic reticulum stress mediates resistance to BCL-2 inhibitor in uveal melanoma cells.
Bellini L, Strub T, Habel N, Pandiani C, Marchetti S, Martel A, Baillif S, Bailly-Maitre B, Gual P, Ballotti R, Bertolotto C.
Cell Death Discov · research-article; journal article · DOI 10.1038/s41420-020-0259-2EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-X<sub>L</sub> inhibitor is overcome by BIM upregulation in ovarian clear cell carcinoma cells.
Inoue-Yamauchi A, Oda H.
Biochem Biophys Res Commun · journal article · DOI 10.1016/j.bbrc.2020.03.139CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263.
Huang T, Ding X, Xu G, Chen G, Cao Y, Peng C, Shen S, Lv Y, Wang L, Zou X.
Cell Death Dis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41419-019-1831-7BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation.
Zhan Y, Wang Y, Qi M, Liang P, Ma Y, Li T, Li H, Dai C, An Z, Qi Y, Wu H, Shao H.
Cell Biosci · research-article; journal article · DOI 10.1186/s13578-019-0322-yCombination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment.
Britt EL, Raman S, Leek K, Sheehy CH, Kim SW, Harada H.
PLoS One · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0219398Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1.
Murray JB, Davidson J, Chen I, Davis B, Dokurno P, Graham CJ, Harris R, Jordan A, Matassova N, Pedder C, Ray S, Roughley SD, Smith J, Walmsley C, Wang Y, Whitehead N, Williamson DS, Casara P, Le Diguarher T, Hickman J, Stark J, Kotschy A, Geneste O, Hubbard RE.
ACS Omega · research-article; journal article · DOI 10.1021/acsomega.9b00611ABT-263 exhibits apoptosis-inducing potential in oral cancer cells by targeting C/EBP-homologous protein.
Yang IH, Jung JY, Kim SH, Yoo ES, Cho NP, Lee H, Lee JY, Hong SD, Shin JA, Cho SD.
Cell Oncol (Dordr) · research-article; journal article · DOI 10.1007/s13402-019-00431-5Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax).
Lever JR, Fergason-Cantrell EA.
Pharmacol Res · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1016/j.phrs.2019.01.040The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
Li H, Wang H, Deng K, Han W, Hong B, Lin W.
Cancer Biomark · research-article; journal article · DOI 10.3233/cbm-181692NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.
Dastur A, Choi A, Costa C, Yin X, Williams A, McClanaghan J, Greenberg M, Roderick J, Patel NU, Boisvert J, McDermott U, Garnett MJ, Almenara J, Grant S, Rizzo K, Engelman JA, Kelliher M, Faber AC, Benes CH.
Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-18-0867ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells.
Lee YC, Wang LJ, Huang CH, Shi YJ, Chang LS.
Cancer Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.canlet.2018.06.019Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines.
Lian BSX, Yek AEH, Shuvas H, Abdul Rahman SF, Muniandy K, Mohana-Kumaran N.
BMC Res Notes · brief-report; journal article · DOI 10.1186/s13104-018-3302-0The Antiarrhythmic Drug, Amiodarone, Decreases AKT Activity and Sensitizes Human Acute Myeloid Leukemia Cells to Apoptosis by ABT-263.
Ketchem CJ, Kucera C, Barve A, Beverly LJ.
Am J Med Sci · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1016/j.amjms.2018.01.011Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis.
Lagares D, Santos A, Grasberger PE, Liu F, Probst CK, Rahimi RA, Sakai N, Kuehl T, Ryan J, Bhola P, Montero J, Kapoor M, Baron M, Varelas X, Tschumperlin DJ, Letai A, Tager AM.
Sci Transl Med · research-article; journal article · DOI 10.1126/scitranslmed.aal3765Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin.
Lee EY, Gong EY, Shin JS, Moon JH, Shim HJ, Kim SM, Lee S, Jeong J, Gong JH, Kim MJ, Lee DH, Park YS, Shin J, Hong SW, Kim YS, Jin DH.
Toxicol In Vitro · journal article · DOI 10.1016/j.tiv.2017.09.023JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against <i>MYCN</i>-amplified small cell lung cancer.
Wang H, Hong B, Li X, Deng K, Li H, Yan Lui VW, Lin W.
Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.21146ABT-263 induces G<sub>1</sub>/G<sub>0</sub>-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro.
Lin QH, Que FC, Gu CP, Zhong DS, Zhou D, Kong Y, Yu L, Liu SW.
Acta Pharmacol Sin · research-article; journal article · DOI 10.1038/aps.2017.78Data on the DNA damaging and mutagenic potential of the BH3-mimetics ABT-263/Navitoclax and TW-37.
Green MM, Shekhar TM, Hawkins CJ.
Data Brief · other; journal article · DOI 10.1016/j.dib.2016.01.013Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.
Nakajima W, Sharma K, Hicks MA, Le N, Brown R, Krystal GW, Harada H.
Cancer Biol Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.1080/15384047.2015.1108485ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW.
Nat Med · research support, non-u.s. gov't; journal article · DOI 10.1038/nm.3048Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.
Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA.
Pediatr Blood Cancer · journal article; research support, n.i.h., extramural · DOI 10.1002/pbc.21433